1-20 of 24
Guillermo Garcia-Manero
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Irene Ganan-Gomez, Tapan M. Kadia, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1319–1326.
https://doi.org/10.1158/1078-0432.CCR-23-2860
Published: 01 April 2024
View article titled, Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Open the PDF for Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax in another window
Includes: Supplementary data
Journal Articles

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Jayastu Senapati, Warren C. Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Courtney D. DiNardo, Elias Jabbour, Jan Burger, Nicholas J. Short, Yesid Alvarado, Nitin Jain, Lucia Masarova, Ghayas C. Issa, Wei Qiao, Joseph D. Khoury, Sherry Pierce, Darla Miller, Koji Sasaki, Marina Konopleva, Kapil N. Bhalla, Gautam Borthakur, Naveen Pemmaraju
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4352–4360.
https://doi.org/10.1158/1078-0432.CCR-23-1429
Published: 01 November 2023
View article titled, Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Open the PDF for Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies in another window
Includes: Supplementary data
Journal Articles

Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero, Jin S. Im
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1938–1951.
https://doi.org/10.1158/1078-0432.CCR-22-2601
Published: 15 May 2023
View article titled, Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Open the PDF for Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

Koichi Takahashi, Feng Wang, Kiyomi Morita, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zahr, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiu Wu, Steven Kornblau, Courtney DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop Kantarjian, Jorge Cortes, Marina Konopleva, Andrew Futreal
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 16.
https://doi.org/10.1158/1557-3265.HEMMAL17-16
Published: 14 December 2017
View article titled, Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)
Journal Articles

c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Angela Nebbioso, Vincenzo Carafa, Mariarosaria Conte, Francesco Paolo Tambaro, Ciro Abbondanza, Joost Martens, Matthias Nees, Rosaria Benedetti, Isabella Pallavicini, Saverio Minucci, Guillermo Garcia-Manero, Francesco Iovino, Gabriella Lania, Concetta Ingenito, Valeria Belsito Petrizzi, Hendrik G. Stunnenberg, Lucia Altucci
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (10): 2542–2555.
https://doi.org/10.1158/1078-0432.CCR-15-2388
Published: 14 May 2017
View article titled, c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Open the PDF for c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero, Hanna J. Khoury, Elias Jabbour, Jeffrey Lancet, Shannon L. Winski, LouAnn Cable, Selena Rush, Lara Maloney, Grant Hogeland, Mieke Ptaszynski, Monica Cabrero Calvo, Zach Bohannan, Alan List, Hagop Kantarjian, Rami Komrokji
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 985–994.
https://doi.org/10.1158/1078-0432.CCR-14-1765
Published: 01 March 2015
View article titled, A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Open the PDF for A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes in another window
Includes: Supplementary data
Journal Articles

5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications

Andres Soriano, Hui Yang, Srdan Verstovsek, William Wierda, Charles Koller, Zeev Estrov, Souzanne Ouzounian, Hagop Kantarjian, Jean Pierre Issa, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B48.
Published: 15 August 2014
View article titled, 5-azacytidine(5- AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications
Journal Articles

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

Yue Wei, Tapan Kadia, Weigang Tong, Ming Zhang, Yu Jia, Hui Yang, Yumin Hu, Francesco Paolo Tambaro, Jean Viallet, Susan O'Brien, Guillermo Garcia-Manero
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3923–3932.
https://doi.org/10.1158/1078-0432.CCR-10-0032
Published: 28 July 2010
View article titled, The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy
Open the PDF for The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

Fadi Braiteh, Andres O. Soriano, Guillermo Garcia-Manero, David Hong, Marcella M. Johnson, Leandro De Padua Silva, Hui Yang, Stefanie Alexander, Johannes Wolff, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6296–6301.
https://doi.org/10.1158/1078-0432.CCR-08-1247
Published: 30 September 2008
View article titled, Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
Open the PDF for Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers in another window
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines

Taichun Qin, Emile M. Youssef, Jaroslav Jelinek, Rong Chen, Allen S. Yang, Guillermo Garcia-Manero, Jean-Pierre J. Issa
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4225–4232.
https://doi.org/10.1158/1078-0432.CCR-06-2762
Published: 18 July 2007
View article titled, Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines
Open the PDF for Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines in another window
Journal Articles

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4628–4635.
https://doi.org/10.1158/1078-0432.CCR-06-0511
Published: 09 August 2006
View article titled, A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-04-2139
Published: 02 May 2005
View article titled, Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Open the PDF for Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View article titled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan, Jeffrey Lancet, Maureen Cooper, Alison Hannah, Guillermo Garcia-Manero, Stephan Faderl, Hagop Kantarjian, Julie Cherrington, Maher Albitar, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 88–95.
https://doi.org/10.1158/1078-0432.CCR-0221-3
Published: 20 January 2004
View article titled, Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
Open the PDF for Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: Follow-Up Results

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Terry L. Smith, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Jean-Pierre J. Issa, Michael Andreeff, Steven M. Kornblau, Charles Koller, Milosav Beran, Michael Keating, Mary Beth Rios, Jenny Shan, Debra Resta, Renaud Capdeville, Kimberly Hayes, Maher Albitar, Emil J. Freireich, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2177–2187.
Published: 01 July 2002
View article titled, Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle>
Open the PDF for Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle> in another window